Pricing issues are keeping Irish patients from having access to nine new drugs — the majority of which are cancer treatments — despite widespread availability across Europe.
Although the drugs have been vetted through the HTA, according to an Irish Times report, they’ve not been approved for patients by the HSE. The drugs have been waiting on average roughly two years for an HSE decision.
According to the report, Pfizer’s breast cancer treatment ibrance and Biogen’s Spinraza.
Roche, Bristol Myers Squibb, Amgen and Sanofi also have drugs on the list.
To read the full report on the Irish Times, click here.